EMRELIS™ (telisotuzumab vedotin-tllv), FDA Approved for Treatment of Adult Patients with Previously Treated Non-Small Cell Lung Cancer, Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for EMRELIS, a first-in-class intravenous therapy for previously treated non-squamous NSCLC with high c-Met protein overexpression.